Recruiting Cultural Adaptation of an Educational Tool in Medullary Thyroid Cancer NCT07142005 Conditions Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +11 more Locations MD Anderson Cancer Center — Houston, Texas, United States View Trial Details
Not Yet Recruiting A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations NCT07048964 Conditions Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +10 more Locations Not specified View Trial Details
Completed QUILT-3.006 for Recurrent Medullary Thyroid Cancer NCT01856920 Conditions Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +10 more Locations NIH Clinical Center — Bethesda, Maryland, United States View Trial Details
Completed Pembrolizumab in Recurrent or Metastatic Medullary Thyroid Cancer NCT03072160 Conditions Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +10 more Locations National Institutes of Health Clinical Center — Bethesda, Maryland, United States View Trial Details
Completed Nintedanib(BIBF1120) in Thyroid Cancer NCT01788982 Conditions Adenocarcinoma, Carcinoma, Carcinoma, Medullary, +17 more Locations A.Z. St. Jan — Bruges, Belgium Hopitaux Universitaires Bordet-Erasme - Institut Jules Bordet — Brussels, Belgium Cliniques Universitaires Saint-Luc — Brussels, Belgium Universitair Ziekenhuis Antwerpen — Edegem, Antwerpen, Belgium View all 27 locations View more locations Show fewer locations Loading locations... View Trial Details
